{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:05:43Z","timestamp":1792137943373,"version":"4.4.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.arteri.2021.02.012","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T18:09:32Z","timestamp":1620324572000},"page":"53-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S1","title":["\u00c1cido bempedoico. Mecanismo de acci\u00f3n y propiedades farmacocin\u00e9ticas y farmacodin\u00e1micas"],"prefix":"10.1016","volume":"33","author":[{"given":"Llu\u00eds","family":"Masana Mar\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Plana Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2021.02.012_bib0090","first-page":"2","article-title":"Bempedoic acid: Everything with a place and purpose","volume":"1","author":"Westerink","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.arteri.2021.02.012_bib0095","doi-asserted-by":"crossref","DOI":"10.2217\/fca-2020-0016","article-title":"Bempedoic acid: a promising novel agent for LDL-C lowering","author":"Agarwala","year":"2020","journal-title":"Future Cardiol."},{"key":"10.1016\/j.arteri.2021.02.012_bib0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/CRD.0000000000000218","article-title":"Bempedoic Acid (ETC-1002): ATP citrate lyase inhibitor review of a first-in-class medication with potential benefit in statin-refractory cases","volume":"27","author":"Zagelbaum","year":"2019","journal-title":"Cardiol Rev."},{"key":"10.1016\/j.arteri.2021.02.012_bib0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2021.02.012_bib0110","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","article-title":"Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: Results of a multicenter, randomized, double-blind, placebo-controlled, paral","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2021.02.012_bib0115","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun."},{"key":"10.1016\/j.arteri.2021.02.012_bib0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res."},{"key":"10.1016\/j.arteri.2021.02.012_bib0125","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jacl.2015.01.002","article-title":"Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia","volume":"9","author":"Lemus","year":"2015","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2021.02.012_bib0130","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/CIRCRESAHA.118.313171","article-title":"Lipids-Lowering Agents","volume":"124","author":"Hegele","year":"2019","journal-title":"Circ Res."},{"key":"10.1016\/j.arteri.2021.02.012_bib0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MOL.0000000000000390","article-title":"ATP-citrate lyase: Genetics, molecular biology and therapeutic target for dyslipidemia","volume":"28","author":"Burke","year":"2017","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.arteri.2021.02.012_bib0140","first-page":"1","article-title":"Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential","volume":"21","author":"Brandts","year":"2020","journal-title":"Expert Opin Investig Drugs."},{"key":"10.1016\/j.arteri.2021.02.012_bib0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","article-title":"Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase","volume":"18","author":"Bilen","year":"2016","journal-title":"Curr Atheroscler Rep."},{"key":"10.1016\/j.arteri.2021.02.012_bib0150","year":"2020","journal-title":"Food and Drug Administration"},{"key":"10.1016\/j.arteri.2021.02.012_bib0155","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40265-020-01308-w","article-title":"Bempedoic Acid: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs."},{"key":"10.1016\/j.arteri.2021.02.012_bib0160","first-page":"1","article-title":"Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy","volume":"9","author":"Tomlinson","year":"2020","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.arteri.2021.02.012_bib0165","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","article-title":"Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial","volume":"13","author":"Lalwani","year":"2019","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2021.02.012_bib0170","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/2047487319864672","article-title":"Bempedoic acid and ezetimibe \u2013 better together","volume":"27","author":"Khan","year":"2020","journal-title":"Eur J Prev Cardiol."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821000462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821000462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:32:50Z","timestamp":1759325570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916821000462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":17,"alternative-id":["S0214916821000462"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2021.02.012","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c1cido bempedoico. Mecanismo de acci\u00f3n y propiedades farmacocin\u00e9ticas y farmacodin\u00e1micas","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2021.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Arteriosclerosis.","name":"copyright","label":"Copyright"}]}}